ISI Web of Knowledge Take the next step  
Web of Science®
 
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Author(s): Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B
Source: NEW ENGLAND JOURNAL OF MEDICINE    Volume: 335    Issue: 9    Pages: 609-616    Published: AUG 29 1996  
Times Cited: 590     References: 27     
Abstract: Background Recently in France, primary pulmonary hypertension developed in a cluster of patients exposed to derivatives of fenfluramine in appetite suppressants (anorexic agents), which are used for weight control. We investigated the potential role of anorexic agents and other suspected risk factors for primary pulmonary hypertension.

Methods In a case-control study, we assessed 95 patients with primary pulmonary hypertension from 35 centers in France, Belgium, the United Kingdom, and the Netherlands and 355 controls recruited from general practices and matched to the patients' sex and age.

Results The use of anorexic drugs (mainly derivatives of fenfluramine) was associated with an increased risk of primary pulmonary hypertension (odds ratio with any anorexic-drug use, 6.3; 95 percent confidence interval, 3.0 to 13.2). For the use of anorexic agents in the preceding year, the odds ratio was 10.1 (95 percent confidence interval, 3.4 to 29.9). When anorexic drugs were used for a total of more than three months, the odds ratio was 23.1 (95 percent confidence interval, 6.9 to 77.7). We also confirmed an association with several previously identified risk factors: a family history of pulmonary hypertension, infection with the human immunodeficiency virus, cirrhosis, and use of cocaine or intravenous drugs.

Conclusions The use of anorexic drugs was associated with the development of primary pulmonary hypertension. Active surveillance for this disease should be considered, particularly since the use of anorexic drugs is expected to increase in the near future. (C) 1996, Massachusetts Medical Society.

Document Type: Article
Language: English
Reprint Address: Abenhaim, L (reprint author), SIR MORTIMER B DAVIS JEWISH HOSP, CTR CLIN EPIDEMIOL & COMMUNITY STUDIES, MONTREAL, PQ H3T 1E2 CANADA
Addresses:
1. MCGILL UNIV, CTR CLIN EPIDEMIOL & COMMUNITY STUDIES, MONTREAL, PQ H3T 1E2 CANADA
2. ANTOINE BECLERE HOSP, SERV PNEUMOL, CLAMART, FRANCE
3. UNIV ILLINOIS, DEPT SURG, CARDIOL SECT, CHICAGO, IL 60680 USA
4. NCI, ROCKVILLE, MD USA
5. CHU LIEGE, INST PATHOL, PHARMACOL LAB, LIEGE, BELGIUM
6. UNIV SHEFFIELD, SECT RESP MED, SHEFFIELD S10 2TN, S YORKSHIRE ENGLAND
7. HAMMERSMITH HOSP, DEPT CARDIOL, LONDON, ENGLAND
8. UNIV HOSP MAASTRICHT, DEPT PULMONOL, MAASTRICHT, NETHERLANDS
9. HOP XAVIER BICHAT, SERV PNEUMOL, PARIS, FRANCE
10. PELLEGRIN HOSP, CTR PHARMACOVIGILANCE, BORDEAUX, FRANCE
Publisher: MASS MEDICAL SOC, 10 SHATTUCK, BOSTON, MA 02115
Subject Category: Medicine, General & Internal
IDS Number: VD425
ISSN: 0028-4793
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
  
Thomson Reuters Logo